Original Investigation  Health Policy September 27, 2024 Treatment Effects in Randomized and Nonrandomized Studies of Pharmacological Interventions: A Meta-Analysis Maximilian Salcher-Konrad, Mary Nguyen, Jelena Savović, et al JAMA Netw Open. 2024;7(9):e2436230. doi:10.1001/jamanetworkopen.2024.36230 Key Points Question  How do treatment effects for drugs compare when obtained from nonrandomi...

Original Investigation  Equity, Diversity, and Inclusion September 24, 2024 Race and Sex Disparities Among Emergency Medicine Chief Residents Jennifer W. Tsai, Mytien Nguyen, Sarah N. Dudgeon, et al JAMA Netw Open. 2024;7(9):e2432679. doi:10.1001/jamanetworkopen.2024.32679 Key Points Question  Do racial disparities for selecting emergency medicine chief residency exist? Findings  ...

Original Investigation  Pediatrics September 25, 2024 Lung Recruitment Before Surfactant Administration in Extremely Preterm Neonates: 2-Year Follow-Up of a Randomized Clinical Trial Francesca Gallini, Domenico Umberto De Rose, Roberta Iuliano, et al JAMA Netw Open. 2024;7(9):e2435347. doi:10.1001/jamanetworkopen.2024.35347 Key Points Question  Did infants who underwent the intubate-recruit-s...

ONLINE FIRST (FREE ACCESS) "ICU TOOLBOX" TOPICAL COLLECTION Editorial Monitoring cardiac output De Backer D., Hajjar L. and Monnet X. "MY GREEN ICU" COLLECTION CorrespondenceHow a green team can rapidly lower the carbon footprint of paracetamol route use in intensive careGisbert-Mora C. et al LATEST ARTICLES Original Noninvasive ventilation on reintubation in patients with obesity and hypoxemic respiratory failure following abdominal surgery: a ...

Original Investigation  September 25, 2024 Fever Prevention in Patients With Acute Vascular Brain Injury: The INTREPID Randomized Clinical Trial David M. Greer, Raimund Helbok, Neeraj Badjatia, et al JAMA. Published online September 25, 2024. doi:10.1001/jama.2024.14745 Key Points Question  Is an automated surface temperature management device effective in prevention of fever in patients with ac...

Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 GBD 2021 Antimicrobial Resistance Collaborators Lancet 2024; 404: 1199-1226 Summary Background Antimicrobial resistance (AMR) poses an important global health challenge in the 21st century. A previous study has quantified the global and regional burden of AMR for 2019, followed with additional publications that provided more detailed estimates for sev...

ORIGINAL ARTICLE Beta-Blocker Interruption or Continuation after Myocardial Infarction Johanne Silvain, Guillaume Cayla, Emile Ferrari, et al N Engl J Med Published August 30, 2024 DOI: 10.1056/NEJMoa2404204 Abstract BACKGROUND The appropriate duration of treatment with beta-blocker drugs after a myocardial infarction is unknown. Data are needed on the safety and efficacy of the interruption of long-term beta-blocker...

ORIGINAL ARTICLE Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk Gerald F. Watts, Robert S. Rosenson, Robert A. Hegele, et al N Engl J Med Published September 2, 2024 DOI: 10.1056/NEJMoa2409368 Abstract BACKGROUND Persistent chylomicronemia is a genetic recessive disorder that is classically caused by familial chylomicronemia syndrome (FCS), but it also has multifactorial causes. The disorder is associated with the risk of rec...

ORIGINAL ARTICLE Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype David J. Jackson, Michael E. Wechsler, Daniel J. Jackson, et al N Engl J Med Published September 9, 2024 DOI: 10.1056/NEJMoa2406673 Abstract BACKGROUND Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. METHODS In these phase 3A, randomized, placebo-contro...

ORIGINAL ARTICLE Ponsegromab for the Treatment of Cancer Cachexia John D. Groarke, Jeffrey Crawford, Susie M. Collins, et al N Engl J Med DOI: 10.1056/NEJMoa2409515 Abstract BACKGROUND Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a circulating cytokine, is elevated in cancer cachexia. In a small, open-label, phase 1b study involving patients with can...